Healio Blog Update: Guideline addresses NAIMI management, prevention for stem cell transplant recipients
A new blog post from Dr. Randy Taplitz highlights updated guidance from ASTCT on managing non-Aspergillus invasive mold infections (NAIMIs) in hematopoietic stem cell transplant recipients — including children and those treated with CAR T-cell therapy. Though rare, these infections can be life-threatening and often present as breakthroughs despite antifungal prophylaxis. The guideline offers expert-informed strategies for diagnosis, treatment and risk mitigation.
“NAIMIs are uncommon but potentially devastating — early recognition and individualized management are key to improving outcomes.”
— Randy Taplitz, MD, FIDSA